| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84376 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
188 |
zyl |
2024-12-19 |
| 84377 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
203 |
WYQ |
2024-12-19 |
| 84378 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
159 |
h |
2024-12-19 |
| 84379 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
169 |
WYQ |
2024-12-19 |
| 84380 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
184 |
wyh |
2024-12-19 |
| 84381 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
192 |
WYQ |
2024-12-19 |
| 84382 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
225 |
kx |
2024-12-19 |
| 84383 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
178 |
h |
2024-12-19 |
| 84384 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
174 |
wyh |
2024-12-19 |
| 84385 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
192 |
zyl |
2024-12-19 |
| 84386 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
215 |
WYQ |
2024-12-19 |
| 84387 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester， ADC试剂 |
196 |
kx |
2024-12-19 |
| 84388 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
178 |
h |
2024-12-19 |
| 84389 |
DBCO-PEG3-acetic-Val-Cit-PAB，主要用于合成抗体偶联药物（ADC） |
175 |
WYQ |
2024-12-19 |
| 84390 |
Mal-PEG4-Val-Ala-PAB-PNP，ADC定制 |
149 |
wyh |
2024-12-19 |
| 84391 |
cas:330970-70-2 Alloc-Val-Ala-OH |
194 |
zyl |
2024-12-19 |
| 84392 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
183 |
h |
2024-12-19 |
| 84393 |
CAS: 2754384-60-4，DBCO-(PEG)3-VC-PAB-MMAE |
168 |
WYQ |
2024-12-19 |
| 84394 |
Fmoc-Gln(Trt)-PAB-OH， ADC试剂 |
186 |
kx |
2024-12-19 |
| 84395 |
CAS: 2994332-18-0 ，DBCO-C4-Val-Cit-PABC-PNP，二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 |
161 |
WYQ |
2024-12-19 |
| 84396 |
cas:159857-60-0，Fmoc-Lys(MMt)-OH，N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 |
272 |
kx |
2024-12-19 |
| 84397 |
DBCO-PEG3-Val-Cit-PAB-PNP，二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
198 |
WYQ |
2024-12-19 |
| 84398 |
NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 |
188 |
h |
2024-12-19 |
| 84399 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
216 |
zyl |
2024-12-19 |
| 84400 |
TCO-PEG4-Val-Cit-PAB-PNP，反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
177 |
WYQ |
2024-12-19 |
| 84401 |
Boc-Val-Cit CAS:870487-08-4 |
255 |
zyl |
2024-12-19 |
| 84402 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
191 |
h |
2024-12-19 |
| 84403 |
cas:252554-78-2，Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH，(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
155 |
kx |
2024-12-19 |
| 84404 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
159 |
h |
2024-12-19 |
| 84405 |
cas:2413428-36-9，MC-Gly-Gly-Phe-Gly，(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
153 |
kx |
2024-12-19 |
| 84406 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
247 |
zyl |
2024-12-19 |
| 84407 |
cas:2353409-52-4，Mal-amido-PEG8-Val-Gly-PAB-OH，马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
120 |
kx |
2024-12-19 |
| 84408 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
135 |
zyl |
2024-12-19 |
| 84409 |
cas:1895916-22-9，MC-Val-Ala-OH， ADC试剂 |
147 |
kx |
2024-12-19 |
| 84410 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，MC-VAL-CIT-阿霉素 |
110 |
kx |
2024-12-19 |
| 84411 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
130 |
h |
2024-12-19 |
| 84412 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
153 |
h |
2024-12-19 |
| 84413 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE)， N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
164 |
kx |
2024-12-19 |
| 84414 |
DOTA-dGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 |
202 |
h |
2024-12-19 |
| 84415 |
DOTA-MGO DOTA-DGlu-(Glu)s-minigastrin |
139 |
h |
2024-12-19 |
| 84416 |
cas:2762518-86-3，NHS Ester-PEG4-Val-Cit-PAB-MMAE， ADC试剂 |
182 |
kx |
2024-12-19 |
| 84417 |
DOTA-scFv-anti-PSMA DOTA-scFv-抗PSMA脂质纳米粒(LNPs) |
195 |
h |
2024-12-19 |
| 84418 |
cas:2353409-45-5，BCN-PEG3-Val-Cit-PFP Ester， ADC试剂 |
157 |
kx |
2024-12-19 |
| 84419 |
cas:2112738-13-1，Mal-amido-PEG2-Val-Cit-PAB-PNP， ADC试剂 |
127 |
kx |
2024-12-19 |
| 84420 |
cas:2055041-39-7，Mal-PEG4-Val-Cit-PAB-OH， ADC试剂 |
180 |
kx |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询